As the CEO or CSO of a biotech company, you need to expedite establishment of in vivo proof-of-concepts and speed-up the selection of new drug candidates that will be compatible with the desired target product profiles. Your investors will want to know how you will secure fast tracking to early clinical studies. For optimising cash flow and eventually maximising company value, you will have to understand and sometimes readjust the prioritisation between studies to stay aligned with the project strategy and objectives. To achieve your goals partnering with an integrated network of reliable preclinical CROs is key for your success.
Any specific issue you want to discuss?